| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2077667 | Cell Stem Cell | 2010 | 4 Pages |
Abstract
Cell therapies derived from pluripotent stem cells are entering the preclinical and early clinical development phase, but eventual translation faces many challenges. We describe a new approach by California to form global public-private “disease team” partnerships to enable new clinical opportunities to be evaluated in the complex regulatory environment.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Alan Trounson, Elona Baum, Don Gibbons, Patricia Tekamp-Olson,